Enhanced Nanoparticle Cell-Entry for Cancer Therapy
Posted Aug 28 2012 8:00pm
Description of Invention: Nanoparticles are being used as a method of drug delivery for the treatment of several diseases, cancer in particular. While the use and versatility of these particles have increased over the years, the speed with which these particles can enter the cells and deliver the drugs remains challenging.
This technology describes a method of modifying nanoparticles to markedly enhance their entry into cancer cells and their delivery of therapeutic drugs. The nanoparticles use a multi-shell calcium phosphate nanocore designed with target-specific siRNA and an endocytosis-enhancing agent. The inventors have shown that the intravenous systemic administration of the enhanced nanoparticles noticeably increases nanoparticle cell-entry along with concomitant delivery of siRNA to cancer cells in vivo. They further demonstrate that the composite calcium phosphate nanoparticle delivery of anti-cancer therapy can preferentially target in vivo tumors and cause tumor growth arrest. Consequently, these modified nanoparticles can exert a greater effect on cancer cells.
Nanoparticle delivery of therapeutic treatments to cancers cells.
Nanoparticle delivery of imaging agents for the identification and monitoring of tumor cells.
Preferentially taken up by cancer cells and not normal cells
Faster uptake into cells than other nanoparticles
Tissue and/or cell specific
Can be customized for targeted therapy
Extremely versatile – can transport a variety of therapeutic agents and the constructs can incorporate siRNA, chemotherapy agents, targeted drugs, pro-drugs, tracers, and radioactive molecules.
Collaborative Research Opportunity: The Kwong Laboratory, Surgery Branch, NCI, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize nanoparticles in anti-cancer therapy. For collaboration opportunities, please contact King F. Kwong, M.D. at firstname.lastname@example.org .
For Licensing Information Please Contact: Whitney Hastings NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-451-7337 Fax: 301-402-0220